Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Repurchasing up to $30M of Shares

NEW YORK (GenomeWeb) – Qiagen has launched the third tranche of a share repurchase program for up to approximately $30 million. 

In a document filed with the US Securities and Exchange Commission, the firm said that a maximum of 2 million shares will be repurchased at a maximum per-share price no greater than 10 percent above the average closing price of the last five trading days prior to the day of purchase on the Frankfurt Stock Exchange. 

The third tranche of the repurchase program lasts until Aug. 31, Qiagen said. In the two previous tranches carried out last year, the firm repurchased more than 2.1 million shares for about $50 million. 

Qiagen said that the repurchased shares will be held in treasury to satisfy obligations from exchangeable debt instruments and/or employee share-based remuneration plans.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.